SCHEDULE 13D/A: Monograph Capital Exits Significant Stake in UroGen Pharma, Files Final Beneficial Ownership Amendment
Beneficial Ownership Amendment
Monograph Capital Partners I, L.P. and its affiliated reporting persons have filed an exit amendment to their Schedule 13D, indicating they no longer beneficially own more than 5% of UroGen Pharma Ltd.'s Ordinary Shares after selling 733,712 shares.
Summary
- Monograph Capital Partners I, L.P. and its affiliated entities (Monograph Capital Partners I GenPar, LP, Monograph Capital Holdings Advisors, LLC, Fred Cohen, and Charles Conn) have filed Amendment No. 1 to their Schedule 13D, serving as a final 'exit filing'.
- The reporting persons sold a total of 733,712 Ordinary Shares of UroGen Pharma Ltd. between May 27, 2025, and June 6, 2025.
- These sales amounted to approximately 1.6% of UroGen Pharma's Ordinary Shares outstanding.
- As of June 5, 2025, the reporting persons collectively beneficially own 838,615 Ordinary Shares, representing approximately 1.8% of the 46,107,451 Ordinary Shares outstanding as of May 5, 2025.
- Fred Cohen, one of the reporting persons, directly owns and has sole voting and investment power over an additional 15,000 Ordinary Shares.
- Due to their reduced ownership, the reporting persons are no longer subject to beneficial ownership reporting requirements under Section 13 of the Securities Exchange Act of 1934.
Sentiment
Score: 5
Explanation: The document is a factual reporting of a change in beneficial ownership and an 'exit filing' by an investment group. It does not contain information that inherently indicates positive or negative performance for the issuer, UroGen Pharma Ltd., but rather a change in an investor's position.
Negatives
- A significant institutional investor, Monograph Capital, has reduced its stake in UroGen Pharma Ltd. below the 5% reporting threshold, indicating a substantial reduction in their investment.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding UroGen Pharma Ltd.'s future operations or financial performance.
Industry Context
This filing is a specific disclosure of a change in beneficial ownership by an investment firm in a single company, UroGen Pharma Ltd. It does not provide broader insights into industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The exit of a significant institutional investor may be interpreted differently by other shareholders, potentially influencing market sentiment and share price.
Next Steps
- The reporting persons are no longer subject to beneficial ownership reporting requirements under Section 13 of the Securities Exchange Act of 1934 with respect to UroGen Pharma Ltd. shares.
Key Dates
| Date | Description |
|---|---|
| 2023-08-04 | Original Schedule 13D filed by the Reporting Persons. |
| 2025-05-05 | Date as of which 46,107,451 Ordinary Shares were issued and outstanding, as reported in UroGen Pharma's Form 10-Q. |
| 2025-05-12 | Date UroGen Pharma Ltd. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-05-27 | Start date of share sales by Monograph Capital Partners I, L.P. |
| 2025-05-28 | Monograph Capital Partners I, L.P. sold 134,149 shares at a weighted average price of $4.01. |
| 2025-05-29 | Monograph Capital Partners I, L.P. sold 38,537 shares at a weighted average price of $3.97. |
| 2025-05-30 | Monograph Capital Partners I, L.P. sold 145,922 shares at a weighted average price of $3.89. |
| 2025-06-05 | Date of event which required the filing of this statement (Reporting Persons no longer beneficially own more than 5% of shares outstanding). Monograph Capital Partners I, L.P. also sold 111,303 shares at a weighted average price of $5.10 on this date. |
| 2025-06-06 | End date of share sales by Monograph Capital Partners I, L.P., with two transactions totaling 85,237 shares at $5.71 and 144,091 shares at $6.01. |
| 2025-06-09 | Date of filing of this Amendment No. 1 to Schedule 13D. |
Keywords
UroGen Pharma Ltd., Monograph Capital Partners, Schedule 13D Amendment, Beneficial Ownership, Share Sale, Exit Filing, Ordinary Shares, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.